Verge Labs launched as an AI-driven platform for drug discovery using a proprietary multimodal dataset of over 12,000 brain transcriptomes paired with clinical data from living patients. The platform's AI-identified targets have validated at 83% accuracy against experimental confirmation, establishing a scalable model for accelerating central nervous system drug development.
Key Points
- AI platform integrates 12,000+ brain transcriptomes with proteomic, genomic data
- Platform targets validated at 83% accuracy across decade of research programs
- First AI-discovered asset completed Phase 1b trial in late 2025
Longevity Analysis
This represents a shift from hypothesis-driven to data-driven drug discovery in neurological disease. By training AI models on comprehensive human brain datasets—including transcriptomes, proteins, imaging, and blood biomarkers—the platform addresses a fundamental gap in how we currently identify disease mechanisms and therapeutic targets. The integration of living patient data into iterative training cycles means the platform continuously decodes what goes wrong in diseased neural tissue and how interventions alter those patterns. For practitioners and researchers, this accelerates the pathway from identifying that something is broken to validating which interventions actually work, compressing timelines that have historically consumed decades for single targets.
Original published by Longevity.Technology.